CASI Pharmaceuticals (CASIF) Work In Process (2025)
CASI Pharmaceuticals' (CASIF) quarterly Work In Process came in at $504000.0 in Q4 2025.
CASI Pharmaceuticals (CASIF) Work In Process (2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 1 years of Work In Process data on file, last reported at $504000.0 in Q4 2025.
- Quarterly Work In Process changed N/A year-over-year to $504000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $504000.0 (changed N/A YoY) and the FY2025 annual result came in at $504000.0, changed N/A from the prior year.
- Work In Process was little changed at $504000.0 in Q4 2025.
- In the past five years, Work In Process ranged from a high of $504000.0 in Q4 2025 to a low of $504000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 504,000.00 |